Teva Pharmaceutical Industries (NYSE:TEVA) has been assigned a $13.00 price target by investment analysts at Royal Bank of Canada in a research note issued to investors on Wednesday. The firm presently has a “sell” rating on the stock. Royal Bank of Canada’s target price indicates a potential downside of 36.80% from the company’s previous close.
TEVA has been the topic of a number of other reports. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Friday, December 15th. Credit Suisse Group reiterated an “underperform” rating and set a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, November 6th. Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, December 28th. Wells Fargo & Co reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, October 5th. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Sunday, November 12th. Eight analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $21.32.
Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.38 during midday trading on Wednesday, hitting $20.57. The stock had a trading volume of 14,830,000 shares, compared to its average volume of 26,880,000. The company has a market cap of $20,710.00, a PE ratio of -3.50, a price-to-earnings-growth ratio of 1.50 and a beta of 0.54. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $37.94. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.
Hedge funds have recently bought and sold shares of the business. San Francisco Sentry Investment Group CA purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $106,000. Bank of Nova Scotia grew its holdings in shares of Teva Pharmaceutical Industries by 8.3% during the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares in the last quarter. Penserra Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $129,000. Americafirst Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter worth about $303,000. Finally, Salem Investment Counselors Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 12.8% during the second quarter. Salem Investment Counselors Inc. now owns 9,400 shares of the company’s stock worth $312,000 after purchasing an additional 1,068 shares in the last quarter. 51.89% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This report was originally reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/24/teva-pharmaceutical-industries-teva-given-a-13-00-price-target-by-royal-bank-of-canada-analysts.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
